Results 31 to 40 of about 2,242,189 (260)

The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy

Journal of Hematology & Oncology, 2019
Background Tamoxifen resistance remains a clinical challenge for hormone receptor-positive breast cancer. Recently, dysregulations in autophagy have been suggested as a potential mechanism for tamoxifen resistance.
Ji Wang, Shuduo Xie, Jingjing Yang, Hanchu Xiong, Yunlu Jia, Yulu Zhou, Yongxia Chen, Xiaogang Ying, Cong Chen, Chenyang Ye, Linbo Wang, Jichun Zhou   +11 more
doaj   +1 more source

Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance

Frontiers in Genetics, 2022
Breast cancer is the leading cause of death in female cancers, and what’s worse, tamoxifen resistance occurs in almost 30% breast cancer patients and has seriously attenuated the therapeutic effect.
Xiulei Zhang, Qian Zhang, Guangzhi Liu
doaj   +1 more source

PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. [PDF]

Genes (Basel)
Background: Estrogen receptor-positive breast cancer accounts for around 70% of all cases. Tamoxifen, an anti-estrogenic inhibitor, is the primary drug used for this type of breast cancer treatment.
Zhang P, Qian N, Lai H, Chen S, Wu K, Luo X, Lei B, Liu M, Cui J.   +8 more
europepmc   +2 more sources

Inhibition of long non-coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer

Tumor Biology, 2017
This study explored the mechanism underlying long non-coding RNA ROR regulating autophagy on Tamoxifen resistance in breast cancer. Cancer tissues and adjacent normal tissues were collected from 74 breast cancer patients.
Yuehua Li, Baohong Jiang, Hongbo Zhu, Xiaofei Qu, Liqin Zhao, Yeru Tan, Yiling Jiang, Mingchu Liao, Xiaoping Wu   +8 more
doaj   +1 more source

Expression analysis elucidates the roles of Nicastrin, Notch4, and Hes1 in prognosis and endocrine-therapy resistance in ER-positive breast cancer patients

Research in Pharmaceutical Sciences, 2023
Background and purpose: Although some proposed mechanisms responsible for tamoxifen resistance have already been present, further study is needed to determine the mechanisms underlying tamoxifen resistance more clearly.
Arad Boustan, Rosa Jahangiri, Asefeh Dahmardeh Ghalehno, Mahdieh Khorsandi, Fatemeh Mosaffa, Khadijeh Jamialahmadi   +5 more
doaj   +1 more source

C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells

BMC Cancer, 2018
Background Tamoxifen is a frontline therapy for estrogen receptor (ER)-positive breast cancer in premenopausal women. However, many patients develop resistance to tamoxifen, and the mechanism underlying tamoxifen resistance is not well understood.
Wei Li, Ling Xu, Xiaofang Che, Haizhou Li, Ye Zhang, Na Song, Ti Wen, Kezuo Hou, Yi Yang, Lu Zhou, Xing Xin, Lu Xu, Xue Zeng, Sha Shi, Yunpeng Liu, Xiujuan Qu, Yuee Teng   +16 more
doaj   +1 more source

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen [PDF]

, 2012
SynthSys is a Centre for Integrative Systems Biology (CISB) funded by BBSRC and EPSRC, reference BB/D019621/1.Background: Estrogen receptors alpha (ER) are implicated in many types of female cancers, and are the common target for anti-cancer therapy ...
Harrison, David J, Kenneth Macleod, Yamaguchi, Azusa, Macleod, Kenneth, Galina Lebedeva, David J Harrison, Lebedeva, Galina, Langdon, Simon P., Langdon, Simon P, Azusa Yamaguchi, Harrison, David J., Simon P Langdon   +11 more
core   +1 more source

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

Molecular Cancer, 2010
Background Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2.
Richer Jennifer K, Edgerton Susan M, Spoelstra Nicole S, Das Partha M, Cittelly Diana M, Thor Ann D, Jones Frank E   +6 more
doaj   +1 more source

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer

Life, 2022
NCOR2 is a co-repressor for estrogen receptor (ER) and androgen receptor (AR). Our group previously identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance via interference of NCOR2 repression on ER.
Ho Tsoi, Ling Shi, Man-Hong Leung, Ellen P. S. Man, Zi-Qing So, Wing-Lok Chan, Ui-Soon Khoo   +6 more
doaj   +1 more source

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer [PDF]

, 2008
Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to
Crilly, M., C McCowan, Donnan, P.T., T P Fahey, McCowan, C., Shearer, J., Fahey, T. P., Thompson, A. M., P T Donnan, Donnan, P. T.; id_orcid, Dewar, J.A., Dewar, J. A., J A Dewar, A M Thompson, Thompson, A.M., Fahey, T.P., M Crilly, J Shearer   +17 more
core   +1 more source